Psyence Biomedical is developing pharmaceutical-grade, naturally sourced psilocybin to treat psychological trauma and resulting diagnosable disorders, including adjustment disorder and alcohol use disorder. Its psilocybin capsules are being evaluated in a Phase IIb study.
Status note The company has no registered products on the market; its new potential psilocybin-based product candidates are either in the preclinical or clinical development phase. The filing names no specific candidates, trials, phases, or indications in the provided excerpts.
Per-asset detail extracted from the 20-F filed 2026-06-22. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.